Pharmacy Practice Amendments
SB 312 makes several targeted changes to Utah’s pharmacy laws. First, it creates a new insurance-code provision requiring health benefit plans to treat a pharmacist as a health care provider for certain consultations tied to pharmacist-prescribed nebulizers, spacers, diabetic supplies, and other prescription drugs or devices authorized under existing pharmacy law, but only when the plan already covers the item and for plans renewed or entered into on or after January 1, 2026. The bill also updates the Pharmacy Practice Act to clarify that pharmacists may prescribe certain devices when needed to ensure the proper delivery of a prescribed drug, specifically including nebulizers, spacers, and diabetic supplies.
The bill further revises pharmacy audit rules. It tightens and clarifies notice, timing, documentation, appeal, and recoupment requirements for audits conducted by pharmacy benefit managers, insurers, third-party administrators, and similar entities. Among other changes, it requires 10 days’ advance written notice for on-site audits, limits the use of extrapolation, restricts recoupment for clerical errors, and preserves pharmacies’ ability to validate claims with pharmacy or provider records. It also adjusts the definition of “eligible pharmacy” under the Charitable Prescription Drug Recycling Program, expanding the types of pharmacies and public or charitable entities that may participate, and makes technical conforming changes throughout the pharmacy code.
SB 312 amends Utah Code sections in both the insurance and pharmacy practice titles, creating new insurer obligations and revising the scope of pharmacist authority and pharmacy audit procedures. It affects health benefit plans, pharmacy benefit managers, pharmacies, pharmacists, and charitable prescription drug recycling participants. The bill also updates statutory definitions used in the Pharmacy Practice Act and the Charitable Prescription Drug Recycling Act, with an effective date of May 7, 2025, and a delayed applicability date for the insurer-provider consultation provision beginning with plans renewed or entered into on or after January 1, 2026.
The bill appears to have broad support and little visible opposition. It advanced unanimously through Senate and House committee votes and passed both chambers without any recorded dissenting votes. The vote history suggests the legislation was viewed as a practical, technical, and consumer-access measure rather than a controversial policy change.
No major contention is reflected in the available materials, and there are no committee transcript excerpts indicating debate. The most likely areas of policy interest are the expanded recognition of pharmacists in insurance reimbursement and consultation settings, the new authority for pharmacists to prescribe delivery-related devices, and the tighter limits on pharmacy audits by PBMs and insurers. Those provisions primarily benefit pharmacists and pharmacies, while potentially constraining auditing entities and insurers; the charitable recycling changes also broaden participation by counties, county health departments, the state health department, and charitable clinics.